Circulating ceramides as biomarkers of cardiovascular disease: evidence from phenotypic and genomic studies.

Research output: Contribution to journalArticlepeer-review


There is a need for new biomarkers of atherosclerotic cardiovascular disease (ACVD), the main cause of death globally. Ceramides, a class of potent bioactive lipid mediators, have signalling roles in apoptosis, cellular stress and inflammation. Recent studies have highlighted circulating ceramides as novel biomarkers of coronary artery disease, type-2 diabetes and insulin resistance. Ceramides are highly regulated by enzymatic reactions throughout the body in terms of their activity and metabolism, including production, degradation and transport. The genetic studies that have been completed to date on the main ceramide species found in circulation are described, highlighting the importance of DNA variants in genes involved in ceramide biosynthesis as key influencers of heritable, circulating ceramide levels. We also review studies of disease associations with ceramides and discuss mechanistic insights deriving from recent genomic studies. The signalling activities of ceramides in vascular inflammation and apoptosis, associations between circulating ceramides and coronary artery disease risk, type-2 diabetes and insulin resistance, and the potential importance of ceramides with regard to ACVD risk factors, such as blood pressure, lipoproteins and lifestyle factors, are also discussed.

Original languageEnglish
Pages (from-to)18-30
Number of pages13
Publication statusPublished - 6 May 2021


  • Biomarkers
  • Ceramides
  • Genetics


Dive into the research topics of 'Circulating ceramides as biomarkers of cardiovascular disease: evidence from phenotypic and genomic studies.'. Together they form a unique fingerprint.

Cite this